Follow us on

Board of Advisors

The advisory board of SMS-oncology brings external perspective and quality authentication to move company forward in its missions.

Edwin Klumper MD PhD MBA

Edwin Klumper  

Edwin carries over 20+ years of experience in Cancer Research and the Pharmaceutical Industry both in Big Pharma as well as small biotech. Trained as an MD, Edwin obtained a PhD in Medicine after devoting 5 years of cancer research on drug resistance and chemosentivity in Leukemia testing panels of 20 drugs on patient samples. He jumpstarted his career as Medical Director for Yew Tree Pharma, a small startup company that developed taxane products and that was later acquired by Bristol Myers Squibb. After serving as local Business Unit Director Oncology for mid-sized Asta Medica, Edwin joined Amgen to successfully build a team to launch Aranesp in The Netherlands, to turn around the Business Unit in the UK, before taking on responsibility for Aranesp Nephrology in Europe as Brand Director at Amgen Headquarters Europe based in Switzerland. With a keen interest in the dynamics of biotech and drug development he Joined Nabi Biopharmaceuticals Europe in Ireland as Vice-President Marketing & Sales to build its commercial operations. After following the executive course ‘Leadership in Biotechnology’ at Harvard Business School in Boston, Edwin decided to combine his business interest with his science and medical background and joined SMS-oncology as co-founder.

Erik Leferink


Erik started as a business developer for MIRAI, a CRO later acquired by Parexel. He founded DOCS International, a clinical consultancy and staffing organization which now employs over 350 staffing consultants and clinical professionals in 9 European countries (DOCS was acquired by ICON Clinical Research in the summer of 2007). Erik is one of the co-founders of SMS-oncology and his main competence is in setting up and developing young service companies that deliver sustainable services to innovative healthcare industries, both in the pharmaceutical and the biotechnology field.

Request for proposal
Subscribe to our oncology feed
Contact us